Hercberg Serge, Ezzedine Khaled, Guinot Christiane, Preziosi Paul, Galan Pilar, Bertrais Sandrine, Estaquio Carla, Briançon Serge, Favier Alain, Latreille Julie, Malvy Denis
UMR U557 Inserm/U1125 Inra/EA3200 Cnam/Univ Paris 13, Bobigny, France 93017.
J Nutr. 2007 Sep;137(9):2098-105. doi: 10.1093/jn/137.9.2098.
This research aimed to test whether supplementation with a combination of antioxidant vitamins and minerals could reduce the risk of skin cancers (SC). It was performed within the framework of the Supplementation in Vitamins and Mineral Antioxidants study, a randomized, double-blinded, placebo-controlled, primary prevention trial testing the efficacy of nutritional doses of antioxidants in reducing incidence of cancer and ischemic heart disease in the general population. French adults (7876 women and 5141 men) were randomized to take an oral daily capsule of antioxidants (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, and 20 mg zinc) or a matching placebo. The median time of follow-up was 7.5 y. A total of 157 cases of all types of SC were reported, from which 25 were melanomas. Because the effect of antioxidants on SC incidence varied according to gender, men and women were analyzed separately. In women, the incidence of SC was higher in the antioxidant group [adjusted hazard ratio (adjusted HR) = 1.68; P = 0.03]. Conversely, in men, incidence did not differ between the 2 treatment groups (adjusted HR = 0.69; P = 0.11). Despite the small number of events, the incidence of melanoma was also higher in the antioxidant group for women (adjusted HR = 4.31; P = 0.02). The incidence of nonmelanoma SC did not differ between the antioxidant and placebo groups (adjusted HR = 1.37; P = 0.22 for women and adjusted HR = 0.72; P = 0.19 for men). Our findings suggest that antioxidant supplementation affects the incidence of SC differentially in men and women.
本研究旨在测试补充抗氧化维生素和矿物质的组合是否可以降低皮肤癌(SC)的风险。该研究是在维生素和矿物质抗氧化剂补充研究的框架内进行的,这是一项随机、双盲、安慰剂对照的一级预防试验,旨在测试营养剂量的抗氧化剂在降低普通人群癌症和缺血性心脏病发病率方面的疗效。法国成年人(7876名女性和5141名男性)被随机分配每天口服一粒抗氧化剂胶囊(120毫克维生素C、30毫克维生素E、6毫克β-胡萝卜素、100微克硒和20毫克锌)或匹配的安慰剂。随访的中位时间为7.5年。共报告了157例各类皮肤癌病例,其中25例为黑色素瘤。由于抗氧化剂对皮肤癌发病率的影响因性别而异,因此对男性和女性分别进行了分析。在女性中,抗氧化剂组的皮肤癌发病率较高[调整后风险比(调整后HR)=1.68;P=0.03]。相反,在男性中,两个治疗组的发病率没有差异(调整后HR=0.69;P=0.11)。尽管事件数量较少,但抗氧化剂组中女性的黑色素瘤发病率也较高(调整后HR=4.31;P=0.02)。抗氧化剂组和安慰剂组之间非黑色素瘤皮肤癌的发病率没有差异(女性调整后HR=1.37;P=0.22,男性调整后HR=0.72;P=0.19)。我们的研究结果表明,补充抗氧化剂对男性和女性皮肤癌发病率的影响存在差异。